Advantage Of Antibody Based Selectivity In The Purification Of Biologics

By Pim Hermans, Frank Detmers, Hendrik Adams, Orjana Terova and Jessica de Rooij, Thermo Fisher Scientific

Advances in bio-therapeutics are generating an increasing range of complex molecules that present unique and often complex purification challenges. By taking advantage of antibody based selectivity, Camelid heavy-chain antibody fragments (VHHs) have proven to be a reliable immuno-affinity chromatography (IAC) solution in the downstream process of biologics. ThermoScientific™ CaptureSelect™ affinity products and analytical tools are developed for the discovery and manufacturing of even the most demanding bio-therapeutics.The affinity resins provide high target purity in  a single step, independent of feedstock.

CAPTURESELECT TECHNOLOGY –UNIQUE AFFINITY PURIFICATION SOLUTION

• Affinity through antibody selectivity: technology based on Camelidsingle domain [VHH] antibody fragments
• Unique VHH screening technology to determine final resin properties such as target specificity, mild elution & ligand stability
• Animal origin free production process (Saccharomyces Cerevisiae)
• Technology used in commercial purification processes